Overview
The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2025-12-01
2025-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
We aim to assess the the efficiency and safety of N-acetylcysteine for prevention of thrombotic events after allogenic hematopoietic stem cell transplantation.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
The First Affiliated Hospital of Soochow UniversityTreatments:
AcetylcysteineBusulfan
Cyclophosphamide
Cytarabine
N-monoacetylcystine
Criteria
Inclusion Criteria:1. Aged 16-70 years old
2. Diagnosed as myeloid malignancies, and about to undergo allo-HSCT;
3. ECOG: 0-2;
4. Expected survival longer than 1 month
Exclusion Criteria:
1. Allergic to any components of NAC;
2. Severe dysfunction of heart, liver, lung and kidney;
3. Relapse before HSCT;
4. A history of bronchial asthma, bronchospasm or moderate / severe gastrohelcosis.